IMMray™ PanCan-d is a unique blood test for the early detection of pancreatic cancer that has the potential to dramatically increase patient survival rates: from 5-8% to up to 49%. Our retrospective studies show that the test is able to detect stage I and stage II pancreatic cancer with an accuracy of 96%. A test with such a high level of accuracy would give clinicians a much greater chance of finding the cancer when it is still resectable by surgical procedures.